Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celularity Inc. on May 20, 2025. The report details a material definitive agreement entered into on the same date regarding the company's debt obligations.
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, or total debt levels. The document focuses exclusively on a specific transaction involving a Convertible Promissory Note.
Material Changes
- Debt Extension: The maturity date of a Convertible Promissory Note dated March 13, 2024, held by YA II PN, Ltd. ("YA"), was extended from May 12, 2025, to August 15, 2025.
- Equity Issuance: In exchange for the extension, the Company issued 100,000 shares of restricted Class A Common Stock to YA.
- Registration Rights: The issued shares include piggyback registration rights, allowing YA to include the resale of these shares in future registration statements filed by the Company.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the disclosure of the unregistered sale of equity securities. The transaction was executed to manage the maturity of existing debt.
Key Facts for Investor Verification
- Verify the total principal amount and interest terms of the Convertible Promissory Note dated March 13, 2024, which was extended.
- Confirm the dilution impact of the 100,000 newly issued restricted shares on existing shareholders.
- Review the Company's current liquidity position to assess the necessity of the debt extension.
- Check for any other outstanding convertible notes or debt instruments nearing maturity.